Oral melanosis after tyrosine kinase inhibition with imatinib for chronic myelogenous leukemia: Report of a case and review of the literature

Dermatology Online Journal

Volumn 17, Issue 5, 2011, Pages

  Wong, Michelle ^a   Sade, Shachar ^a   Gilbert, Melanie ^a   Klie, Hagen B E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; MELANIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CERVICAL LYMPHADENOPATHY; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; IMMUNOHISTOCHEMISTRY; MELANOSIS; ORAL BIOPSY; ORAL MELANOSIS; PALATE DISEASE; PALATE PIGMENTATION; STAINING; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; HARD PALATE; MOUTH DISEASE; PATHOLOGY; REVIEW;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MELANINS; MELANOSIS; MOUTH DISEASES; PALATE, HARD; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 79960704589     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Alexandrescu, D. T., Constatin, C. A., Farzanmehr, H., & Kauffman, C. L. (2008). Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatology Online Journal, 14 (7), 7. [PubMed]
2. Lerman MA, Karimbux N, Guze KA, Woo SB. (2009). Pigmentation of the hard palate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Jan;107(1):8-12. [PubMed]
3. McPherson T, Sherman V, & Turner R. (2009). Imatinib-associated hyperpigmentation, a side effect that should be recognized. Journal of European Academy of Dermatology and Venereology, 23 (1), 82-83. [PubMed]
4. Arora, B., Kumar, L., Sharma, A., Wadhwa, J., & Kochupillai, V. (2004). Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Annals of Oncology, 15 (2), 358-359. [PubMed]
5. Hasan, S., Dinh, K., Lombardo, F., Dawkins, F., & Kark, J. (2003). Hypopigmentation in an African patient treated with imatinib mesylate: A case report. Journal of National Medical Assocation, 95 (8), 722-724. [PubMed]
6. Ena, P., Chiarolini, F., Siddi, G. M., & Cossu, A. (2004). Oral lichenoid eruption secondary to imatinib (Glivec). Journal of Dermatological Treatment, 15, 253-255. [PubMed]
7. Lewis, D. M. (2009). Diffuse pigmentation of the palate. Oklahoma Dental Association Journal, 100 (8), 24-25. [PubMed]
8. Mattsson U, Halbritter S, Serikoff EM, Christerson L, Warfvinge G. (2011) Oral pigmentation in the hard palate associated with imatinib mesylate therapy: A report of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. May;111(5):e12-6 [PubMed]
9. Basso, F. G., Boer, C. C., Torrazan, M., Cintra, M. L., de Magahles, M. H., da Silva Santos, P., et al. (2009). Skin and oral lesions associated to imatinib mesylate therapy. Support Care Cancer, 17, 465-468. [PubMed]
10. Singh, N., & Bakhshi, S. (2007). Imatinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia. Journal of Pediatric Hematology/Oncology, 29 (3), 208-209. [PubMed]
11. Gagari E, Rand MK, Tayari L, Vastardis H, Sharma P, Hauschka PV, Damoulis PD. (2006). Expression of stem cell factor and its receptor, c-kit, in human oral mesenchymal cells. Eur J Oral Sci. Oct;114(5):409-15. [PubMed]